Induction of plasminogen activator inhibitor by products released from platelets.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Circulation

• Publication date

  1990-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.82.4.1485PMID 2401077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transforming growth factor‐α

  1990cited by this paper
• Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C-mediated mechanism.

  1989cited by this paper
• Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha.

  1989cited by this paper
• Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C- mediated mechanism [see comments]

  1989cited by this paper
• Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.

  1989cited by this paper
• Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.

  1989cited by this paper
• Serpin-resistant mutants of human tissue-type plasminogen activator

  1989cited by this paper
• Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.

  1989cited by this paper
• Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacologic implications.

  1989cited by this paper
• Coronary thrombolysis and the new biology.

  1989cited by this paper
• Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.

  1989cited by this paper
• Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.

  1988cited by this paper
• Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.

  1988cited by this paper
• Transforming growth factor‐α: Structure and biological activities

  1988cited by this paper
• Transforming growth factor alpha.

  1988cited by this paper
• Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

  1988cited by this paper
• Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation.

  1988cited by this paper
• Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor.

  1988cited by this paper
• Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).

  1988cited by this paper
• Plasminogen activator inhibitor type 1: Biochemical, biological and clinical aspects

  1988cited by this paper
• 135 Protein S (PS) in patients with deep venous thrombosis (DVT) under heparin therapy

  1988cited by this paper
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell

  1987cited by this paper
• Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits.

  1987cited by this paper
• Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis.

  1986cited by this paper
• A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators.

  1986cited by this paper
• Blood Platelet Plasminogen Activator Inhibitor: Two Different Pools of Endothelial Cell Type Plasminogen Activator Inhibitor in Human Blood

  1986cited by this paper
• A Sensitive Assay, Specific for Endothelial Cell Type Plasminogen Activator Inhibitor in Blood Plasma

  1986cited by this paper
• Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells

  1986cited by this paper
• Determination of tissue plasminogen activator and its "fast" inhibitor in plasma.

  1986cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper
• The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related.

  1985cited by this paper
• Identification of a reversible inhibitor of plasminogen activators in blood plasma

  1985cited by this paper
• Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene.

  1985cited by this paper
• Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.

  1983cited by this paper
• A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

  1983cited by this paper
• Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation.

  1983cited by this paper
• Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.

  1983cited by this paper
• Influence of thyroid hormone on the in vitro translational activity of specific mRNAs in the rat heart.

  1983cited by this paper
• Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

  1980cited by this paper
• A study of proteases and protease-inhibitor complexes in biological fluids

  1978cited by this paper
• Inhibition of plasmin by normal and antiplasmin-depleted human plasma.

  1976cited by this paper
• The sulphite precipitation method for fibrinogen measurement; its use on small samples in the presence of fibrinogen degradation products.

  1976cited by this paper
• Platelet size in man.

  1975cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• The transformation of hemostatic platelet plugs in normal and Factor IX deficient dogs.

  1968cited by this paper

• Platelets and Fibrinolysis

  2017cites this paper
• is downregulated by smooth muscle cells Type 1 plasminogen activator inhibitor synthesis of endothelial cells

  2011cites this paper
• Effects of Stress-Hemoconcentration on the Coagulation Cascade

  2011cites this paper
• COMPARISON OF THE ASSOCIATION OF PAI-1actWITH THE METABOLIC SYNDROME MARKERS IN CAUCASIAN AND BLACK SOUTH AFRICAN WOMEN

  2007cites this paper
• Shear Stress Induces Hepatocyte PAI-1 Gene Expression Through Cooperative Sp1/Ets-1 Activation of Transcription

  2006cites this paper
• Human aortic vascular smooth muscle cells digest extracellular matrix by elaboration of plasminogen activators: Implications for atherogenesis

  2005cites this paper
• Mouse Models for Arterial Thrombosis: Does Clotting Make a Difference in Human Cardiovascular Disease?

  2004cites this paper
• Inhibitors of Fibrinolytic Components Play Different Roles in the Formation and Removal of Arterial Thrombus in Mice

  2002cites this paper
• Ramipril Prior to Thrombolysis Attenuates the Early Increase of PAI-1 in Patients with Acute Myocardial Infarction

  2002cites this paper
• Suppression of Cell Proliferation by Tissue Plasminogen Activator During the Early Phase After Balloon Injury Minimizes Intimal Hyperplasia in Hypercholesterolemic Rabbits

  2001cites this paper
• Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin

  2001cites this paper
• Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfusion.

  2000cites this paper
• Impaired Endogenous Fibrinolysis in Diabetes Mellitus: Mechanisms and Therapeutic Approaches

  2000cites this paper
• The Fat Mouse: A Powerful Genetic Model to Study Hemostatic Gene Expression in Obesity/NIDDM

  2000cites this paper
• Burton Elias Sobel, MD: a conversation with the editor. Interview by William Clifford Roberts.

  1999cites this paper
• Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.

  1999cites this paper
• Association of plasma levels of activated protein C with recanalization of the infarct-related coronary artery after thrombolytic therapy in acute myocardial infarction.

  1999cites this paper
• Hemostatic Gene Expression and Vascular Disease in Obesity: Insights from Studies of Genetically Obese Mice

  1999cites this paper
• Differential Role of Components of the Fibrinolytic System in the Formation and Removal of Thrombus Induced by Endothelial Injury

  1999cites this paper
• Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals.

  1998cites this paper
• The adipocyte and hemostatic balance in obesity: studies of PAI-1.

  1998cites this paper
• Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice.

  1998cites this paper
• Platelets and Endothelial Cells Act in Concert to Delay Thrombolysis – Evidence from an In Vitro Model of the Human Occlusive Thrombus

  1998cites this paper
• Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction.

  1998cites this paper
• Attenuation of Thrombolysis-induced Increase of Plasminogen Activator Inhibitor-1 by Intravenous Enalaprilat

  1998cites this paper
• Elevated Expression of Transforming Growth Factor-β in Adipose Tissue from Obese Mice

  1997cites this paper
• Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity

  1997cites this paper
• The Fat Mouse: A Powerful Genetic Model to Study Elevated Plasminogen Activator Inhibitor 1 in Obesity/NIDDM

  1997cites this paper
• Regulation of the synthesis of plasminogen activator inhibitor type 1 (PAI-1): pathogenetic mechanism of atherosclerosis in diabetes mellitus?

  1997cites this paper
• Hyperinsulinemia increases plasma activity of PAI-1 in vivo independently of an acute phase reaction

  1997cites this paper
• The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM.

  1997cites this paper
• The human fibrinolytic system.

  1996cites this paper
• Gene expression and regulation of plasminogen activator inhibitor type I in hepatic stellate cells of rat liver.

  1996cites this paper
• Proteins of the Fibrinolytic System in Human Thrombi

  1996cites this paper
• High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi.

  1996cites this paper
• Inhibitors of fibrinolysis are elevated in atherosclerotic plaque.

  1996cites this paper
• Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

  1995cites this paper
• Serial changes of plasma plasminogen activator inhibitor activity in acute myocardial infarction: difference between thrombolytic therapy and direct coronary angioplasty.

  1995cites this paper
• Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.

  1995cites this paper
• Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases.

  1994cites this paper
• High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.

  1994cites this paper
• PAI-1 released from cultured human endothelial cells delays fibrinolysis and is incorporated into the developing fibrin clot*

  1994cites this paper
• Plasma lipoprotein (a) levels and fibrinolytic activity in acute myocardial infarction.

  1994cites this paper
• Circadian variation in fibrinolytic activity in patients with variant angina.

  1994cites this paper
• Fibrinolytic Effect of Gemfibrozil Versus Placebo Administration in Response to Venous Occlusion

  1993cites this paper
• Attenuated Fibrinolysis and Accelerated Atherogenesis in Type II Diabetic Patients

  1993cites this paper
• Type 1 plasminogen activator inhibitor synthesis of endothelial cells is downregulated by smooth muscle cells.

  1993cites this paper
• Plasma lipoprotein(a) levels and fibrinolytic activity in patients with unstable angina.

  1993cites this paper
• Inhibition of Endothelial Cell Expression of Plasminogen Activator Inhibitor Type-1 by Gemfibrozil

  1993cites this paper
• Biological risk factors for restenosis after percutaneous transluminal coronary angioplasty.

  1993cites this paper
• Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy.

  1993cites this paper
• Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury.

  1993cites this paper
• Antiplatelet therapy in coronary heart disease. Emerging strategies for the treatment and prevention of acute myocardial infarction.

  1993cites this paper
• The hemostatic system and coronary heart disease.

  1993cites this paper
• Fibrinolytic activity after vessel wall injury.

  1992cites this paper
• Induction of Endothelial Cell Expression of the Plasminogen Activator Inhibitor Type 1 Gene by Thrombosis In Vivo

  1992cites this paper
• Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis.

  1992cites this paper
• Direct Effects of Gemfibrozil on the Fibrinolytic System: Diminution of Synthesis of Plasminogen Activator Inhibitor Type 1

  1992cites this paper
• Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.

  1992cites this paper
• Thrombin antagonists and antiplatelet agents.

  1992cites this paper
• New developments in thrombolytic therapy.

  1992cites this paper
• Thrombus resistance to lysis and reocclusion after thrombolysis: the role of platelets.

  1991cites this paper
• Mediators of Induction of Augmented Expression of Plasminogen Activator Inhibitor Type-1 in Hep G2 Cells by Platelets

  1991cites this paper
• Blood Vessel and Fibrinolysis

  1991cites this paper
• Circadian variation of fibrinolytic activity in blood.

  1991cites this paper
• Regulation of PAI-1 gene expression

  1991cites this paper
• Platelets and coronary heart disease: potential psychophysiologic mechanisms.

  1991cites this paper
• Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta.

  1991cites this paper
• Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis.

  1991cites this paper
• Seminars in thrombosis, thrombolysis and vascular biology. 3. Platelet activity in cardiovascular disease.

  1991cites this paper
• Impaired fibrinolysis and risk of thromboembolism.

  1991cites this paper
• Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

  1991cites this paper